An 8-year-old girl, who underwent pars plana lensectomy and vitrectomy for non-infectious uveitis, was treated with a dexamethasone intravitreal implant (Ozurdex^®, Allergan Inc., Irvine CA), because of the persistence of cystoid macular edema. The implant migrated into the anterior chamber; however, no cornea edema was detected and a complete resolution of macular edema was observed.

Resumen Objetivo: Determinar las modificaciones de la curvatura posterior de la córnea en pacientes a los que se realizó queratomileusis subepitelial asistida por laser miópico en el período de abril a noviembre 2011. Método: Fueron estudiados 15 pacientes (29 ojos), a los que se realizó queratomileusis subepitelial asistida por laser miópico. Se analizaron variables como edad, sexo, equivalente esférico, paquimetría preoperatoria, cantidad de ablación, estroma residual y diferencia de elevación posterior corneal, esta última obtenida del mapa de diferencia del tomógrafo Pentacam HR con medición preoperatoria, al mes y tres meses de la cirugía. Se realizó análisis de regresión múltiple. Resultados: El equivalente esferico, la paquimetria, cantidad de ablacion y el estroma residual se encontraron dentro de los parametros de seguridad establecidos. La diferencia promedio de la elevacion posterior corneal fue de 3,3 μm al mes, disminuyendo a 2,4 μm a los tres meses. Se observo relacion con la cantidad de ablacion y el estroma residual. Conclusiones: La queratomileusis subepitelial asistida por laser determinó modificaciones en la superficie corneal posterior, las cuales fueron más evidentes en el primer mes del posoperatorio. El estroma residual fue el factor más relacionado con estas modificaciones. Palabras clave: LASEK, elevación corneal posterior, paquimetría, estroma residual, total de ablación. Abstract Purpose: To determine the posterior corneal surface forward shift in myopic patients after laser-assisted subepithelial keratectomy from April to November 2011. Material and methods: Fifteen patients (29 eyes) were submitted to laserassisted subepithelial keratectomy surgery. Age, sex, spherical equivalent, preoperative corneal thickness, total ablation, residual bed thickness and variations in the posterior corneal surface elevation were evaluated. Posterior corneal surface elevation maps were assessed by Pentacam HR tomography and compared with the data of maps obtained prior to the surgery, one and 3 months after the procedure. Results: The spherical equivalent, pachymetry, microns of ablation and residual bed thickness were within the established parameters. The posterior corneal surface displayed a forward shift of 3,3 μm after a month and 2,4 μm three months later. A relation was found between total ablation, and residual bed thickness. Stepwise lineal multiple regression was used. Conclusions: The use of the laserassisted subepithelial keratectomy determined a forward shift of the posterior corneal surface in the early postoperative that gradually decreased. Residual bed thickness was a relevant factor associated to this change.

Age-related macular degeneration (AMD) is a chronic disease affecting the retina and is the most common cause of blindness in the ageing population in the developed world. Correct and timely diagnosis and classification allows physicians to estimate which patients are at high risk of progressing to more advanced stages of the disease In February 2012, 23 Latin American experts met in Cartagena, Colombia, to develop a Consensus on AMD. This paper summarizes the main points of the discussions including definitions, diagnosis, antiangiogenic treatments, and hopes for the future. Dry AMD remains untreatable but results from promising Phase II trials are awaited eagerly. Antiangiogenics, such as the licensed vascular endothelial growth factor (VEGF) inhibitors, aflibercept and ranibizumab, have revolutionized the treatment of wet AMD in recent years. These drugs work by inhibiting the choroidal neovascularization that causes the rapid vision loss in wet AMD. Another antiangiogenic, bevacizumab, is also commonly used off-label, but is not approved currently for intraocular use. However, barriers to treatment compliance, due to the frequency of monthly injections, can also affect the efficacy of these antiangiogenic therapies. Aflibercept has a longer duration of action compared with other treatments and thereby offers reduced injection frequency. By relieving patients of the need for monthly visits, it can help reduce the growing burden of AMD patients on healthcare resources.